VIRGINIA RETIREMENT SYSTEMS ET Al Invests $2.17 Million in TG Therapeutics, Inc. $TGTX

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 39,531 shares of the biopharmaceutical company's stock, valued at approximately $2,172,000.

Several other hedge funds have also modified their holdings of TGTX. EverSource Wealth Advisors LLC boosted its holdings in TG Therapeutics by 51.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 365 shares during the period. Maryland State Retirement & Pension System raised its stake in shares of TG Therapeutics by 2.0% during the fourth quarter. Maryland State Retirement & Pension System now owns 19,899 shares of the biopharmaceutical company's stock valued at $593,000 after purchasing an additional 393 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of TG Therapeutics by 1.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,406 shares of the biopharmaceutical company's stock valued at $1,135,000 after purchasing an additional 441 shares during the period. Smartleaf Asset Management LLC lifted its position in shares of TG Therapeutics by 16.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 3,147 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 454 shares in the last quarter. Finally, HB Wealth Management LLC lifted its position in shares of TG Therapeutics by 6.7% during the first quarter. HB Wealth Management LLC now owns 7,514 shares of the biopharmaceutical company's stock worth $250,000 after purchasing an additional 475 shares in the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Stock Up 1.4%

Shares of NASDAQ:TGTX opened at $55.39 on Friday. The firm has a market cap of $8.48 billion, a PE ratio of 20.22, a price-to-earnings-growth ratio of 2.34 and a beta of 1.67. The company has a fifty day simple moving average of $53.63 and a 200 day simple moving average of $43.61. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. TG Therapeutics, Inc. has a 12-month low of $26.76 and a 12-month high of $59.30.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.26). The company had revenue of $240.34 million for the quarter, compared to analyst estimates of $229.77 million. TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.TG Therapeutics's revenue was up 70.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.17 earnings per share. On average, equities research analysts anticipate that TG Therapeutics, Inc. will post 0.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Jefferies Financial Group reaffirmed a "buy" rating and set a $83.00 price target on shares of TG Therapeutics in a report on Monday, June 22nd. Weiss Ratings reiterated a "hold (c+)" rating on shares of TG Therapeutics in a report on Wednesday, July 29th. HC Wainwright restated a "buy" rating and set a $78.00 target price on shares of TG Therapeutics in a research note on Tuesday, September 1st. Bank of America lifted their target price on TG Therapeutics from $17.00 to $20.00 and gave the stock an "underperform" rating in a research report on Tuesday, July 7th. Finally, Zacks Research cut TG Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Monday. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $63.00.

TG Therapeutics Profile

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for B-cell diseases and autoimmune disorders. The company's research and development programs are centered on therapies that target B cells, which play an important role in several immune-mediated conditions.

TG Therapeutics' principal product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved by the U.S. Food and Drug Administration for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.